drugset / Trial / NCT06750471

Dupixent Study for Alternate Administration

NCT06750471

RandomizedParallel-groupOpen-labelTreatment

Summary

Investigators will investigate an alternate Dupilumab administration schedule in patients with recurrent chronic rhinosinusitis with nasal polyposis, who have a history of full endoscopic sinus surgery and are on appropriate topical medical therapies. Specifically, investigators will investigate if the alternate schedule of drug administration is non-inferior in both subjective and objective outcomes.

Timeline

Start
2021-10-14
Primary completion
2025-12
Completion
2025-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dupilumab Monoclonal antibody 300 mg Subcutaneous